Mechanism of Action - ReveraGen BioPharma
Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes - ScienceDirect
Pharma News | Actinium, Santhera, Gilead, Seres, BMS, Boehringer
WATCH: Vamorolone Clinical Trials in Duchenne - Webinar Recording - Parent Project Muscular Dystrophy
Vamorolone Trial for DMD Finishes Pivotal First Part, Results Awaited
Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial. - Abstract - Europe PMC
Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit: Molecular Therapy
ReveraGen BioPharma's DMD Drug Vamorolone Gets FDA Fast Track Designation - Muscular Dystrophy Association
Vamorolone inhibits inflammatory signaling in macrophage and heart... | Download Scientific Diagram
Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy - Jett Foundation
Vamorolone Post-Trial Access
![Webinar] Vamorolone (VBP15) Clinical Trials in Duchenne - January 2017 - YouTube](https://i.ytimg.com/vi/h1owg21J0Wc/maxresdefault.jpg "Webinar] Vamorolone (VBP15) Clinical Trials in Duchenne - January 2017 - YouTube")
Webinar] Vamorolone (VBP15) Clinical Trials in Duchenne - January 2017 - YouTube
PDF) Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial
VISION-DMD newsletter launched at Phase 2 of clinical trial of Vamorolone - Action Duchenne
Phase 2a preliminary study results
Vamorolone treatment following disease induction reduces the severity... | Download Scientific Diagram
Clinical Trial Alert: Phase 2 Study of Vamorolone in Adults with BMD - Quest | Muscular Dystrophy Association
1st Patient Dosed in Pilot Trial of Vamorolone for Becker MD | Medication May Work With Fewer Side Effects Than Corticosteroids | Muscular Dystrophy News Today
VISION-DMD End Event: Vamorolone Clinical Trial Results • World Duchenne
Investigational steroid mirrors prednisone's benefits while taming its side effects | Children's National
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study | PLOS Medicine
Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completion of the VISION-DMD Study - Jett Foundation
Santhera and ReveraGen: Vamorolone NDA Mid-Cycle Review with FDA – Defeat Duchenne Canada
Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function | Neurology
Vamorolone - Wikipedia
